Regulations and compliance · Practical guide

Annex 11 vs 21 CFR Part 11: which applies to your process?

An EU GMP system can hold files outside 21 CFR Part 11 scope, and Part 11 is not limited to pharmaceutical manufacturing. Identify the process, required records and their actual use. The comparison helps you document applicability before choosing technical controls and tests.

Table of contents

At a glance

When does Annex 11, Part 11 or both apply?

Annex 11 concerns computerised systems used in GMP-regulated activities. Part 11 concerns certain electronic records and signatures within FDA’s regulatory scope. Both can apply to one process for different reasons. Start with the activity and the underlying recordkeeping obligation, then identify the authoritative electronic evidence. Location, product name, cloud hosting or a US customer alone does not determine applicability.

  • The activity determines the EU GMP relevance; recordkeeping obligation and usage define the Part 11 scope.
  • A hybrid workflow requires a clear assignment of paper records, electronic data, and decisions.
  • The validity determination serves as the basis for control assessment, not as a conformity statement.

1. Begin with the decision regarding the system support

First, describe what the process functionally accomplishes: for example, the documented manufacture of a batch, the assessment of a material property, or the management of internal travel expenses. Identify which information supports a regulated decision. A system name such as ERP or document management does not answer this question.

As a practical operational aid, an initial statement specifying activity, responsibility scope, and key documentation is sufficient. Supplement this by identifying who trusts which data. An application may have multiple intended uses; labeling the entire organization as compliant with Part 11 obscures these distinctions.

Sources: [1] [2] [3]

2. Annex 11 considers the system in GMP activities

The principle of Annex 11 includes computer-based systems that are used as part of GMP-regulated activities. The application should be validated, the IT infrastructure qualified. The risk reference includes patient safety, data integrity and product quality. Therefore, the focus is not solely on the question of whether a signature is made electronically.

This comparison relates to human medicinal product GMP. The current EudraLex index references Annex 11 in the January 2011 revision. The EU GMP guidelines and their integration into European medicinal product law differ from a US federal regulation. A consultation draft does not supersede the listed version.

Sources: [1] [4]

3. Part 11 requires a specific FDA documentation level

§11.1 relates, among other things, to electronic records that are created, modified, retained, archived, retrieved, or transferred in accordance with FDA regulations. The underlying technical requirements are commonly referred to as Predicate Rules. Establish this basis, rather than relying solely on industry practices or an export market.

A specific example is §211.188 relating to batch manufacturing and control recordkeeping within the applicable Drug CGMP domain. Part 11 expands the existing recordkeeping requirements to include specifications for electronic records and signatures. However, it does not establish a universal mandate for electronic documentation of every internal file. The FDA Guidance from 2003 clarifies its more limited interpretation through requirements for specific records and actual usage.

Compare requirements within the respective application area
Comparison pointEU-GMP Annex 11 (2011)21 CFR Part 11
Framework EU-GMP Guidelines for computerized systems in GMP activities. U.S. federal regulation on electronic records and signatures within the specified FDA domain.
Starting point GMP-relevant use of the system; Principle and No. 1. The applicable FDA record-keeping requirement or submission; § 11.1(b).
Lifecycle Own sections on suppliers, periodic evaluation, disruptions, and operational continuity (No. 3, 11, 13, 16). These topics are not addressed as separate sections with identical titles; additional obligations from relevant FDA regulations must also be reviewed.
Change history No. 9 also specifies the documented reason for a change or deletion of GMP-related data. § 11.10(e) references time-stamped audit trails and the retention of prior information; further technical requirements may apply.
Electronic Signature No. 14 specifies effect within the organization, permanent linkage, as well as date and time. Detailed rules regarding declarations, linking, and signature controls; §§ 11.50 to 11.300, including § 11.100(c).
Open Systems No separate section with this designation; risks and access control remain relevant. Section 11.30 addresses additional controls for open systems.

Sources: [2] [5] [3]

4. Use a concise decision pathway

The following sequence is an independent work aid. It is not a legally mandated form and does not replace evaluation of the specific marketing authorization, manufacturing, or study context. An unknown response is recorded as an open scope question and is not implicitly considered a no.

Own decision support: from activity to documentation
StepQuestion to askDocumented result
1 Is this use part of an activity regulated under EU GMP in the considered context? Activities and GMP relevance; accordingly, applicability of Annex 11.
2 Which FDA regulation requires documentation or what relevant submission is on file? Record-keeping, regulatory basis, and where applicable, exceptions.
3 Is the required evidence maintained electronically or actually used electronically? Key record and role of a paper printout.
4 Are electronic signatures used as a signature equivalent? Signature purpose to be evaluated separately; no automatic obligation.
5 Which responses are supported, and which remain open? Accountable, open-source and reason for re-evaluation.

Sources: [1] [2] [3]

5. Example: three cases with different starting points

The cases expressly presuppose the described regulatory scope. In particular, Case B demonstrates a logical scope combination: the assumption of lack of EU-GMP applicability must be substantiated on a factual basis within the actual project; mere geographic location outside the EU would not suffice.

Example: Application suitability matrix, no product assessment
Incident and Primary PurposeAssumptionsResults and next task
A: Electronic Batch Recording in the EU Human Drug GMP Process EU-GMP Activity; no relevant FDA record-keeping requirement or submission identified. Annex 11: yes. Part 11: in this case not derived. Document EU requirements and justification.
B: Electronic batch record in accordance with §211.188 US Drug CGMP Scope defined; the process in the example is not assigned to the considered EU-GMP regime. Part 11: Relevant under these assumptions. Annex 11 does not follow automatically.
C: Common electronic batch record for both regulatory jurisdictions EU GMP activities and US record-keeping obligations; electronic data reflect decisions. Both are considered. Joint inspections with separate source anchors and unambiguously attributable documentation are reviewed.

Sources: [1] [2] [5] [3]

6. Clarify paper and electronic records based on actual practice

The FDA identifies a narrowly defined paper-based scenario: when required documentation is entirely maintained on paper and the regulated activity is directly based on that paper record, the classification may differ from that of significant electronic use. The actual business practice is decisive, not merely the presence of a SOP reference.

If a printout is signed while personnel are electronically filtering, recalculating, or using the data for decision-making, the label "paper process" is insufficient. Map the pathway from origin to decision. Identify additional electronic content and information not captured by the printout. Simply placing a document in two locations does not eliminate the scope or the obligation to obtain the required validation evidence.

Sources: [3] [2]

7. Do not confuse Scope, Signature, and Implementation Policy

Part 11 distinguishes electronic records and electronic signatures. The use of an electronic record does not require an electronic signature for every action. Assess which type of signature is required by the specific process or underlying regulation and evaluate how this requirement is actually implemented.

The 2003 FDA Guidance outlines a limited enforcement policy for certain Part 11 requirements. It does not repeal Part 11 and does not eliminate the requirements of the Predicate Rules. Similarly, it does not waive requirements from Annex 11. Therefore, an EU-USA process cannot be broadly simplified based on a single FDA enforcement notice.

Sources: [2] [3] [1]

8. Record the conclusion about applicability and its rationale

For a small team, a concise and portable decision-making approach is more practical than an extensive regulatory reference document lacking alignment with actual workflow. The technically responsible party defines the intended use; QA or the relevant quality function supports regulatory alignment, IT provides input on data pathways and system boundaries. The exact decision authority depends on your organization's structure.

Review the classification if the intended use, markets, data handling, or submission pathway changes. The addition of new features alone does not necessarily trigger a new regulatory area; however, a new use of the same feature may be relevant. Based on this assessment, establish requirements and validation evidence.

  • Identify the activity, relevant decision, and responsible area.
  • Justify EU-GMP applicability for this use.
  • Record the FDA recordkeeping requirement or applicable submission and cite the source.
  • Assign relevant records, including paper and electronic components.
  • Purpose of signature to be separately addressed; ambiguities to be visibly indicated.
  • Document open items, decision authority, and specific reasons for changes.

Sources: [1] [2] [3]

Project experience and collaboration

Map EU and FDA requirements to the same data flow

Your team selects an electronic record actually used in its GMP process. We examine the EU framework and applicable FDA record requirement separately, then map shared controls and additional requirements for signatures, change history or retention. This avoids duplicate tests while preserving meaningful differences. For a new US business, identifying the relevant records may come first. For an existing system, the priority may be assessment of evidence already available.

Frequently asked questions about Annex 11 vs Part 11

Does Part 11 automatically apply once we supply medicines to the USA?

Not every application falls solely under Part 11 due to the US market. It applies primarily to electronic records maintained pursuant to FDA regulations and electronic submissions to the FDA (§ 11.1(b)). For the manufacture or testing of pharmaceuticals intended for the US market, records required under Part 211 typically apply when they are maintained electronically or used in an electronic format. Determine the specific recordkeeping obligation; an Office document without such a connection is not automatically deemed Part 11 relevant.

Sources: [2] [3]

Is Annex 11 the European version of Part 11?

No. Related control topics exist, but different starting points and regulatory levels apply. Annex 11 addresses computerised systems within GMP-controlled activities. Part 11 covers specific electronic records and signatures within the FDA domain. Therefore, both may be relevant for common processes.

Sources: [1] [2]

Can a system be subject to both regulatory domains simultaneously?

Yes, if both its use and the relevant records meet the intended use requirements. Document these conditions. A later shared access or change control should then have separate source anchors and appropriate evidence, rather than establishing two fully independent review programs without a substantive rationale.

Sources: [1] [2]

Does a signed paper copy satisfy Part 11?

Not automatically. According to FDA interpretation, the requirement for documentation and actual use must be considered. When electronic data are used for regulated activities, the term cannot simply be excluded from the electronic scope. Additionally, verify which required information is available exclusively in electronic form.

Sources: [3]

Is a cloud-based system required to be compliant with EU GMP Annex 11?

No. Storage in a cloud is not an independent trigger of the record scope. First, the applicability is determined. Only after that do questions about access control, responsibilities and, if necessary, open or closed systems follow. The technical mode of operation does not replace these steps.

Sources: [2]

Must every Part 11 record be electronically signed?

From Part 11 alone, no such blanket obligation follows. Distinguish the requirements for electronic records from those for actually used electronic signatures. For a specific signature, its professional purpose and the applicable underlying regulations are decisive.

Sources: [2] [3]

Does a manufacturer's statement suffice to define the scope?

It can provide information but does not automatically capture the actual processes, record-keeping obligations, and data usage. The user must justify the mapping. Supplier documentation is then reviewed for relevant coverage; a general product description does not substitute for a documented data usage decision.

Sources: [1] [3]

Does the Annex-11 draft from 2025 already apply to this comparison?

The EudraLex Index reviewed on 6 October 2026 continues to show the January 2011 revision in the human medicinal product area. This comparison refers to this version. A draft may be considered separately for preparation purposes but must not be treated as an officially valid substitute version.

Sources: [4] [1]

Do we need a separate scope assessment for each file?

Group similar records and uses in a meaningful way. It is important that different responsibilities or decision purposes remain visible. A common record group may suffice; a single, general statement covering all data from a complex system may obscure relevant differences.

Sources: [2] [3]

When should the assignment be re-evaluated?

When changes affect the origin of the change—for example, a new regulated use, additional documentation requirements, a transition from paper-based to electronic decision-making, or a modified submission process—specify such circumstances in your change management procedure. A fixed deadline does not replace event-driven evaluation.

Sources: [1] [3]

Sources and review date

Source date: 6 October 2026. The eCFR display was consolidated up to 2 October 2026. EU references pertain to Human Medicinal Product GMP and the listed Annex 11 version from January 2011; draft versions are not considered enforceable requirements. Examples and matrices are internal reference tools.

  1. EU GMP Annex 11: Computerised SystemsRevision January 2011, Effective Date 30.06.2011; listed in the human medicinal product section on 06.10.2026. Relevant provisions: Principle; §§1–4; §§5–10; §§11–17
  2. 21 CFR Part 11 — Electronic Records; Electronic SignatureseCFR: Title 21 consolidated through 02.10.2026; Title 21 last amended on 30.09.2026. The display does not constitute a claim of a Part 11 amendment on this date. Citations: §11.1(a)–(e) and sector-specific exemptions (f)–(p); §11.2; §11.3(b)(4),(5),(6),(7),(9); §11.10(a)–(k); §11.30; §§11.50, 11.70, 11.100, 11.200, 11.300
  3. FDA: Part 11 — Scope and Application, Original-PDFOriginal cover page August 2003, Pharmaceutical CGMPs; Contains nonbinding recommendations. Currently listed by FDA as Final. Reference locations: I. Introduction, printed pages 1–2; III.A, page 4; III.B.1–2, pages 5–6; III.C.1–5, pages 6–8
  4. European Commission: EudraLex Volume 4Retrieval date: 06.10.2026; Human medicinal products section implements Annex 11 Revision January 2011. References: Human medicines; Annexes; Annex 11
  5. 21 CFR §211.188: Batch production and control recordseCFR updated as of 02.10.2026; displayed on 06.10.2026. Citations: §211.188(a); §211.188(b)(1)–(13)

Sources checked: .

Daniel Herrmann, Daniel Herrmann Consulting

Daniel Herrmann Consulting

Applicability and targeted review of evidence

Daniel Herrmann Consulting supports you in defining your specific process and the appropriate documentation requirements. The scope and responsibilities are aligned with actual needs.

  • GAMP 5 consulting →

    Understand how GAMP 5, EU GMP Annex 11 and 21 CFR Part 11 apply to your systems. We translate the relevant requirements into proportionate validation work and evidence your team can defend in an audit.

Send a project enquiry Customer testimonials →